Molecular markers of response to anti-PD1 therapy in advanced hepatocellular carcinoma

By sjmartinez • September 12, 2022

Haber PK, Castet F, Torres-Martin M, Andreu-Oller C, Puigvehí M, Maeda M, Radu P, Dufour JF, Verslype C, Czauderna C, Marquardt JU, Galle PR, Vogel A, Bathon M, Meyer T, Labgaa I, Digklia A, Roberts LR, Mohamed Ali MA, Mínguez B, Citterio D, Mazzaferro V, Finkelmeier F, Trojan J, Özdirik B, Müller T, Schmelzle M, Bejjani A, Sung MW, Schwartz ME, Finn RS, Thung S, Villanueva A, Sia D, Llovet JM. Molecular markers of response to anti-PD1 therapy in advanced hepatocellular carcinoma. Gastroenterology. 2022 Sep 12:S0016-5085(22)01039-3. doi: 10.1053/j.gastro.2022.09.005. Epub ahead of print. PMID: 36108710.

Tags: biomarkers, Hematology/Oncology, Hepatocellular carcinoma, immunotherapy, predictors of response, Publications

Phase Ib/II trial of talimogene laherparepvec alone and with pembrolizumab in advanced solid tumors with liver metastases and hepatocellular carcinoma

Hecht JR, Oberoi A, Garralda Cabanas E, Jae Chon H, Digklia A, Rottey S, Martin Jimenez M, Chaney M, Hippenmeyer J, Lawrence T, Liu K,[...]

Biology, care, and outcomes of gestational breast cancers: a review

Duggirala N, Zhang S, Master A, Rao R, Kapoor NS, Bardia A, Lipsyc-Sharf M. Biology, care, and outcomes of gestational breast cancers: a review. Breast[...]

Yoo C, Ueno M, Klümpen HJ, Kelley RK, Vogel A, Furuse J, Ren Z, Yau T, Chan SL, Ozaka M, Oh SC, Gu S, Park[...]